High-Dose Influenza Vaccine Linked to Lower Alzheimer Risk in Seniors

Immunization Intensity and the Pathogenesis of Cognitive Decline

Influenza represents a substantial clinical threat to the geriatric population, often exacerbated by immunosenescence (the progressive decline in immune system function associated with aging) and various chronic comorbidities [1]. While annual vaccination is the standard of care, older patients frequently exhibit diminished antibody responses to conventional vaccines, necessitating the use of high-dose formulations to achieve adequate seroconversion [2]. Beyond the prevention of respiratory infection, recent epidemiological data suggest a correlation between routine immunizations and a decreased incidence of Alzheimer dementia [3]. This potential neuroprotective effect is supported by animal models where influenza vaccination appears to modulate systemic immune tolerance and reduce the accumulation of amyloid-beta (the primary protein component of plaques found in the brains of patients with Alzheimer dementia) [4]. To determine if immunization intensity influences cognitive outcomes, researchers recently investigated whether administering a high-dose influenza vaccine provides greater protection against the development of dementia compared to standard-dose formulations in older adults.

Target Trial Emulation in a Large Claims Database

The researchers conducted a retrospective cohort study using data spanning 2014 to 2019 from a comprehensive US health care claims database. The study population included 164,797 adults aged 65 years or older who had at least two years of continuous medical and pharmaceutical coverage. To ensure the analysis focused strictly on incident cases, all eligible participants had no previous diagnostic or pharmacotherapeutic indicators of cognitive impairment at baseline. Vaccinations were identified using both product names and Current Procedural Terminology codes (a standardized system used to report medical procedures). To address the inherent limitations of observational research, the investigators utilized target trial emulation (a methodological framework designed to mimic the rigorous structure and causal inference of a randomized controlled trial using observational data). This approach aligns patient eligibility, treatment assignment, and the precise start of the observation period with vaccination dates. This alignment prevents immortal time bias, a statistical error that occurs when a period of follow-up passes during which the outcome cannot occur, artificially skewing survival or disease-free rates. The researchers further adjusted for measured confounding and mitigated selection bias using inverse probability weighting (a statistical technique that balances treatment groups by weighting individuals based on their likelihood of receiving a specific intervention). The primary outcome of incident Alzheimer dementia was defined using a combination of diagnostic codes and the dispensing of specific medications, such as anticholinesterase inhibitors and memantine. Participants were followed for up to 3 years postvaccination. By applying these rigorous methods, the study provides Class II evidence (data from a well-designed observational study with a control group) that high-dose inactivated influenza vaccines are associated with a decreased risk of incident dementia in older adults, offering clinicians more robust data when considering vaccine formulations for their geriatric patients.

Comparative Cohort Characteristics and Risk Reduction

The study population was divided into two distinct cohorts based on the formulation of the inactivated influenza vaccine received. The high-dose group was the larger of the two, comprising 120,775 unique participants and accounting for 185,183 person-trials. This cohort had a mean age of 74.4 years (standard deviation 5.5) and was 57.3% female. In comparison, the standard-dose group included 44,022 unique participants and 53,918 person-trials. The standard-dose cohort was slightly younger on average, with a mean age of 73.0 years (standard deviation 6.1), and had a similar sex distribution at 56.4% female. When evaluating the primary clinical outcome, the researchers found that the high-dose vaccine was associated with a significantly lower risk of Alzheimer dementia during months 1 to 25 postvaccination. To quantify the clinical impact for practicing physicians, the investigators calculated the number needed to treat, which represents the number of patients who must receive the high-dose formulation instead of the standard-dose to prevent one additional case of the disease. The minimum number needed to treat for the high-dose vaccine was 185.2 at the 25-month mark. For clinicians, this suggests a measurable absolute risk reduction within a relatively short clinical timeframe, adding a potential cognitive benefit to the established infectious disease advantages of high-dose formulations in the elderly.

Sex-Specific Variations in Neuroprotective Associations

Secondary analyses revealed that the association between high-dose vaccination and reduced Alzheimer dementia risk varied significantly when stratified by sex. Among female participants, the risk reduction persisted longer, spanning months 1 to 13 postvaccination. To achieve this clinical benefit in women, the researchers calculated a minimum number needed to treat of 416.7, indicating the number of female patients who would need to receive the high-dose formulation rather than the standard-dose vaccine to prevent one additional case of Alzheimer dementia during that period. The clinical profile for male participants differed in both timing and statistical robustness. In men, the risk reduction was significant only during months 17 to 24 postvaccination. Furthermore, this association in the male cohort reached statistical significance only within the intention-to-treat analysis (a methodological approach that analyzes participants based on the vaccine they were originally assigned to receive rather than the treatment they actually completed). Despite the narrower window of significance, the absolute impact was more concentrated, with a minimum number needed to treat for men of 232.6. These sex-specific variations suggest that the neuroprotective timeline may differ between men and women, a nuance physicians should consider when evaluating the broader cognitive benefits of annual immunization.

Clinical Considerations and Data Limitations

While the observed risk reduction provides a compelling case for high-dose formulations, clinicians must interpret these findings within the context of several study constraints. A primary limitation identified by the researchers was the follow-up duration of 3 years or less, a timeframe that may not fully capture the long-term progression of neurodegenerative pathology. Because the analysis utilized a health care claims database, the study also lacked sociodemographic, lifestyle, biomarker, and mortality data. The absence of information regarding patient education levels, physical activity, smoking status, and genetic markers (such as the apolipoprotein E epsilon 4 allele) means that residual confounding cannot be entirely ruled out despite the use of inverse probability weighting to adjust for measured variables. The biological mechanism driving the association between high-dose vaccination and lower dementia risk remains a subject of ongoing investigation. It is currently unclear whether the clinical benefit stems from superior protection against influenza infection and its subsequent systemic inflammatory cascade, or if it results from non-infection-related mechanisms, such as a more robust modulation of the innate immune system that may clear neurotoxic proteins. For the practicing physician, this study provides Class II evidence that selecting a high-dose inactivated influenza vaccine over a standard-dose version for patients aged 65 and older is associated with a measurable decrease in incident Alzheimer dementia. However, further prospective research is required to determine if this effect is sustained beyond the three-year mark and to clarify the specific immunological pathways involved before recommending high-dose vaccines explicitly for dementia prevention.

References

1. Veronese N, Domínguez LJ, Ganci A, et al. Influenza vaccination in older people: a geriatrician’s perspective. Aging Clinical and Experimental Research. 2025. doi:10.1007/s40520-025-03086-5

2. Carlock MA, Allen JD, Hanley HB, Ross TM. Longitudinal assessment of human antibody binding to hemagglutinin elicited by split-inactivated influenza vaccination over six consecutive seasons. PLoS ONE. 2024. doi:10.1371/journal.pone.0301157

3. Bukhbinder AS, Ling Y, Hasan O, et al. Risk of Alzheimer’s Disease Following Influenza Vaccination: A Claims-Based Cohort Study Using Propensity Score Matching. Journal of Alzheimer s Disease. 2022. doi:10.3233/jad-220361

4. Yang Y, He Z, Xing Z, et al. Influenza vaccination in early Alzheimer’s disease rescues amyloidosis and ameliorates cognitive deficits in APP/PS1 mice by inhibiting regulatory T cells. Journal of Neuroinflammation. 2020. doi:10.1186/s12974-020-01741-4